Gerald Chan, Chairman and CEO, Morningside Group

Leadership in Innovation
Wednesday, September 9, 2016

[soundcloud url=”https://api.soundcloud.com/tracks/223818332″ params=”color=ff5500&auto_play=false&hide_related=false&show_comments=true&show_user=true&show_reposts=false” width=”100%” height=”166″ iframe=”true” /]

Gerald Chan is the co-founder of Morningside, a private investment group with venture, private equity and property investments. In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Gerald serves on the boards of Advanced Cell Diagnostics, Stealth BioTherapeutics, Synchroneuron, Apellis, Atea, Kezar, Nucana, Aduro, VTI and Matrivax. Gerald is a member of the Global Advisory Council of the International Society for Stem Cell Research, the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health and the advisory boards of the Cold Spring Harbor Conferences Asia, the Johns Hopkins Nanjing Center and the Columbia University Center for Radiological Research. He is a trustee of Fudan University in Shanghai and chairs the Board of Overseers of Morningside College of the Chinese University of Hong Kong. He is a member of the Council on Foreign Relations, New York.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow in Scotland have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University.